Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.210
+0.050 (1.58%)
At close: Oct 2, 2025, 4:00 PM EDT
3.240
+0.030 (0.93%)
After-hours: Oct 2, 2025, 7:51 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 299 employees as of December 31, 2024. The number of employees increased by 31 or 11.57% compared to the previous year.
Employees
299
Change (1Y)
31
Growth (1Y)
11.57%
Revenue / Employee
n/a
Profits / Employee
-$860,532
Market Cap
346.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | 91 | 34 | 59.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RCKT News
- 23 days ago - Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. - Barrons
- 6 weeks ago - FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy - Benzinga
- 6 weeks ago - US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial - Reuters
- 6 weeks ago - Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease - Business Wire
- 7 weeks ago - DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - PRNewsWire
- 2 months ago - Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire